


Highlights of This Issue 2493

SMALL MOLECULE THERAPEUTICS

- 2495**  **Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers**
Joel D. Maust, Christy L. Frankowski-McGregor, Armand Bankhead III, Diane M. Simeone, and Judith S. Sebolt-Leopold
- 2507** **Androgen Receptor Inhibitor Enhances the Antitumor Effect of PARP Inhibitor in Breast Cancer Cells by Modulating DNA Damage Response**
Ahrum Min, Hyemin Jang, Seongyeong Kim, Kyung-Hun Lee, Debora Keunyoung Kim, Koungh Jin Suh, Yaewon Yang, Paul Elvin, Mark J. O'Connor, and Seock-Ah Im
- 2519** **Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer**
Hiroshi Tanaka, Hitoshi Sase, Toshiyuki Tsukaguchi, Masami Hasegawa, Hiromi Tanimura, Miyuki Yoshida, Kiyooki Sakata, Toshihiko Fujii, Yukako Tachibana, Kenji Takanashi, Atsuko Higashida, Kiyoshi Hasegawa, Yoshiyuki Ono, Nobuhiro Oikawa, and Toshiyuki Mio
- 2530** **Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy**
Bruno Gomes, Gregory Driessens, Derek Bartlett, Danying Cai, Sandra Cauwenberghs, Stefano Crosignani, Deepak Dalvie, Sofie Denies, Christopher P. Dillon, Valeria R. Fantin, Jie Guo, Marie-Claire Letellier, Wenlin Li, Karen Maegley, Reece Marillier, Nichol Miller, Romain Pirson, Virginie Rabolli, Chad Ray, Nicole Streiner, Vince R. Torti, Konstantinos Tsaparikos, Benoit J. Van den Eynde, Martin Wythes, Li-Chin Yao, Xianxian Zheng, Joseph Tumang, and Manfred Kraus
- 2543** **Targeting Lineage-specific MITF Pathway in Human Melanoma Cell Lines by A-485, the Selective Small-molecule Inhibitor of p300/CBP**
Rui Wang, Yupeng He, Valerie Robinson, Ziping Yang, Paul Hessler, Loren M. Lasko, Xin Lu, Anahita Bhathena, Albert Lai, Tamar Uziel, and Lloyd T. Lam

- 2551** **PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide**
Fumi Higuchi, Alexandria L. Fink, Juri Kiyokawa, Julie J. Miller, Mara V.A. Koerner, Daniel P. Cahill, and Hiroaki Wakimoto
- 2564** **XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB**
Mei Ming, Wenjun Wu, Bingqing Xie, Madina Sukhanova, Weige Wang, Sabah Kadri, Shruti Sharma, Jimmy Lee, Sharon Shacham, Yosef Landesman, Natalia Maltsev, Pin Lu, and Y. Lynn Wang
- 2575**  **Dual Targeting of Aurora Kinases with AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia with Distinct Post-Mitotic Outcomes**
Marc Payton, Hung-Kam Cheung, Maria Stefania S. Ninniri, Christian Marinaccio, William C. Wayne, Kelly Hanestad, John D. Crispino, Gloria Juan, and Angela Coxon
- 2586** **Nano-delivery of RAD6/Translesion Synthesis Inhibitor SMI#9 for Triple-negative Breast Cancer Therapy**
Nadia Saadat, Fangchao Liu, Brittany Haynes, Pratima Nangia-Makker, Xun Bao, Jing Li, Lisa A. Polin, Smiti Gupta, Guangzhao Mao, and Malathy P. Shekhar
- 2598** **Carbonic Anhydrase XII Inhibitors Overcome P-Glycoprotein-Mediated Resistance to Temozolomide in Glioblastoma**
Iris C. Salaroglio, Prashant Mujumdar, Laura Annovazzi, Joanna Kopecka, Marta Mellai, Davide Schiffer, Sally-Ann Poulsen, and Chiara Riganti
- 2610** **Sorafenib and Carfilzomib Synergistically Inhibit the Proliferation, Survival, and Metastasis of Hepatocellular Carcinoma**
Chao Jiang, Rui Xu, Xiao-Xing Li, Yu-Feng Zhou, Xiao-Yi Xu, Yang Yang, Hui-Yun Wang, and X.F. Steven Zheng

LARGE MOLECULE THERAPEUTICS

- 2622** **A Human Ribonuclease Variant and ERK-Pathway Inhibitors Exhibit Highly Synergistic Toxicity for Cancer Cells**
Trish T. Hoang, I. Caglar Tanrikulu, Quinn A. Vatland, Trieu M. Hoang, and Ronald T. Raines

Table of Contents

- 2633** Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates 
Christopher S. Neumann, Kathleen C. Olivas, Martha E. Anderson, Julia H. Cochran, Steven Jin, Fu Li, Luke V. Loftus, David W. Meyer, Jason Neale, Jay C. Nix, Paul G. Pittman, Jessica K. Simmons, Michelle L. Ulrich, Andrew B. Waight, Abbie Wong, Margo C. Zaval, Weiping Zeng, Robert P. Lyon, and Peter D. Senter
- 2643** Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide–Generating Agents Improves the Therapeutic Effects of Nanomedicines
Waliul Islam, Jun Fang, Takahisa Imamura, Tomas Etrych, Vladimir Subr, Karel Ulbrich, and Hiroshi Maeda
- 2654** RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE 
Sreedhar Reddy Suthe, Hang-Ping Yao, Tian-Hao Weng, Chen-Yu Hu, Liang Feng, Zhi-Gang Wu, and Ming-Hai Wang
- 2665** MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FR α Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity 
Xin Cheng, Jing Li, Keigo Tanaka, Utpal Majumder, Andrew Z. Milinichik, Arielle C. Verdi, Christopher J. Maddage, Katherine A. Rybinski, Shawn Fernando, Danielle Fernando, Megan Kuc, Keiji Furuuchi, Frank Fang, Toshimitsu Uenaka, Luigi Grasso, and Earl F. Albone
- CANCER BIOLOGY AND TRANSLATIONAL STUDIES**
- 2676** mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells
Stacia L. Koppenhafer, Kelli L. Goss, William W. Terry, and David J. Gordon
- 2689** ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK–AKT–mTOR Signaling Pathway
Khoa Nguyen, Yuanqing Yan, Bin Yuan, Abhishek Dasgupta, Jeffrey Sun, Hong Mu, Kim-Anh Do, Naoto T. Ueno, Michael Andreeff, and V. Lokesh Battula
- 2702** A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors
Chester E. Chamberlain, Michael S. German, Katherine Yang, Jason Wang, Henry VanBrocklin, Melanie Regan, Kevan M. Shokat, Gregory S. Ducker, Grace E. Kim, Byron Hann, David B. Donner, Robert S. Warren, Alan P. Venook, Emily K. Bergsland, Danny Lee, Yucheng Wang, and Eric K. Nakakura
- 2710** Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase
Jin H. Song, Neha Singh, Libia A. Luevano, Sathish K.R. Padi, Koichi Okumura, Virginie Olive, Stephen M. Black, Noel A. Warfel, David W. Goodrich, and Andrew S. Kraft
- 2722** The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models 
Florian Handle, Martin Puhr, Georg Schaefer, Nicola Lorito, Julia Hoefer, Martina Gruber, Fabian Guggenberger, Frédéric R. Santer, Rute B. Marques, Wytske M. van Weerden, Frank Claessens, Holger H.H. Erb, and Zoran Culig
- 2732** Targeting Peroxisome Proliferator-Activated Receptor γ to Increase Estrogen-Induced Apoptosis in Estrogen-Deprived Breast Cancer Cells 
Ping Fan, Balkees Abderrahman, Tina S. Chai, Smitha Yerrum, and V. Craig Jordan
- 2746** Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer
Tilman Todenhöfer, Roland Seiler, Craig Stewart, Igor Moskalev, Jian Gao, Simroop Ladhar, Alireza Kamjabi, Nader Al Nakouzi, Tetsuharo Hayashi, Stephen Choi, Yuzhuo Wang, Sebastian Frees, Mads Daugaard, Htoo Zarni Oo, Pascale Fisel, Matthias Schwab, Elke Schaeffeler, James Douglas, Jörg Hennenlotter, Jens Bedke, Ewan A. Gibb, Ladan Fazli, Arnulf Stenzl, and Peter C. Black
- 2756** Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
Alexandra Lacey, Erik Hedrick, Yating Cheng, Kumaravel Mohankumar, Melanie Warren, and Stephen Safe

Table of Contents


- 2767** Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type
Yemin Wang, Shary Yuting Chen, Shane Colborne, Galen Lambert, Chae Young Shin, Nancy Dos Santos, Krystal A. Orlando, Jessica D. Lang, William P.D. Hendricks, Marcel B. Bally, Anthony N. Karnezis, Ralf Hass, T. Michael Underhill, Gregg B. Morin, Jeffrey M. Trent, Bernard E. Weissman, and David G. Huntsman

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 2780** Association of Imatinib Plasma Concentration and Single-nucleotide Polymorphisms with Adverse Drug Reactions in Patients with Gastrointestinal Stromal Tumors
Qiang Zhang, Jianghao Xu, Yi Qian, Liang Chen, Qingya Li, Kangjing Xu, Ming Chen, Luning Sun, Zhongyuan He, Li Yang, Diancai Zhang, Linjun Wang, Xiaofeng Sun, Yongqing Wang, Hao Xu, and Zekuan Xu


- 2788** Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer
Yu Sunakawa, Kaoru Mogushi, Heinz-Josef Lenz, Wu Zhang, Akihito Tsuji, Takehiro Takahashi, Tadamichi Denda, Ken Shimada, Mitsugu Kochi, Masato Nakamura, Masahito Kotaka, Yoshihiko Segawa, Hiroaki Tanioka, Yuji Negoro, Miriana Moran, Stephanie H. Astrow, Jack Hsiang, Craig Stephens, Masashi Fujii, and Wataru Ichikawa

- 2796** Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer
Niveditha Nerlakanti, Jiqiang Yao, Duy T. Nguyen, Ami K. Patel, Alexey M. Eroshkin, Harshani R. Lawrence, Muhammad Ayaz, Brent M. Kuenzi, Neha Agarwal, Yunyun Chen, Steven Gunawan, Rezaul M. Karim, Norbert Berndt, John Puskas, Anthony M. Magliocco, Domenico Coppola, Jasreman Dhillon, Jingsong Zhang, Subramaniam Shymalagovindarajan, Uwe Rix, Youngchul Kim, Ranjan Perera, Nicholas J. Lawrence, Ernst Schonbrunn, and Kiran Mahajan

 **AC icon indicates AuthorChoice**
For more information please visit www.aacrjournals.org

ABOUT THE COVER

The yeast RAD6 homologues HHR6A (a.k.a. RAD6A or UBE2A) and HHR6B (a.k.a. RAD6B or UBE2B) encode ubiquitin conjugating enzymes or E2s that play a central role in translesion DNA synthesis (TLS), damage-induced mutagenesis and proteolysis. Consistent with RAD6 function, treatment of breast cancer cells with a RAD6-selective small molecule inhibitor SMI#9 restores chemosensitivity by inhibition of TLS. Delivery of SMI#9 is challenging due to its poor aqueous solubility. Saadat and colleagues synthesized SMI#9 as a prodrug-gold nanoparticle (GNP) conjugate to overcome its solubility limitations and to effectively deliver therapeutic SMI#9 to triple negative breast cancers (TNBCs). As depicted on the cover, both blank and SMI#9 conjugated GNPs are endocytosed into the TNBC cells but cell death is only induced by SMI#9-GNP as detected by acridine orange/ethidium bromide staining. GNPs delivering SMI#9 prodrug exhibited improved in vivo pharmacokinetics and inhibited TNBC growth in vivo. The GNP platform allows for SMI#9 conjugation and delivery to treat TNBCs, a breast cancer subtype with poor prognosis and lacking targeted therapies.



Molecular Cancer Therapeutics

17 (12)

Mol Cancer Ther 2018;17:2493-2810.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/17/12>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/17/12>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.